Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Total Current Liabilities (2020 - 2025)

Candel Therapeutics' Total Current Liabilities history spans 4 years, with the latest figure at $14.2 million for Q4 2023.

  • On a quarterly basis, Total Current Liabilities rose 152.61% to $14.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $14.2 million, a 152.61% increase, with the full-year FY2023 number at $14.2 million, up 152.61% from a year prior.
  • Total Current Liabilities hit $14.2 million in Q4 2023 for Candel Therapeutics, up from $10.3 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CADL hit a ceiling of $14.2 million in Q4 2023 and a floor of $4.4 million in Q3 2021.
  • Historically, Total Current Liabilities has averaged $6.6 million across 4 years, with a median of $5.5 million in 2022.
  • The widest YoY moves for Total Current Liabilities: up 152.61% in 2023, down 4.31% in 2023.
  • Tracing CADL's Total Current Liabilities over 4 years: stood at $4.7 million in 2020, then increased by 13.77% to $5.4 million in 2021, then increased by 4.72% to $5.6 million in 2022, then surged by 152.61% to $14.2 million in 2023.
  • Business Quant data shows Total Current Liabilities for CADL at $14.2 million in Q4 2023, $10.3 million in Q3 2023, and $8.2 million in Q2 2023.